N/A
Manufactured by Novartis Pharmaceuticals Corporation
50,952 FDA adverse event reports analyzed
Last updated: 2026-04-14
DEFERASIROX is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. The most commonly reported adverse reactions for DEFERASIROX include DEATH, DIARRHOEA, SICKLE CELL ANAEMIA WITH CRISIS, PYREXIA, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DEFERASIROX.
Out of 26,183 classified reports for DEFERASIROX:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 50,952 FDA FAERS reports that mention DEFERASIROX. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, DIARRHOEA, SICKLE CELL ANAEMIA WITH CRISIS, PYREXIA, NAUSEA, HAEMOGLOBIN DECREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Novartis Pharmaceuticals Corporation in connection with DEFERASIROX. Always verify the specific product and NDC with your pharmacist.